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Abstract
In order to measure the effects of HFE (haemochromatosis) upon iron uptake, stable expression of wild-type and C282Y,
H63D and S65C mutant HFE cDNA was established in HEK 293 cells. Control cells were transfected with empty vector.
Expression of HFE mRNA and protein was detected in the cell lines transfected with HFE cDNA, but not in the control cell
line. The ferritin concentration in wild-type cells cultured in 40 WM ferric ammonium citrate was 69% of that in control cells
and 81% of that in C282Y cells. The ferritin concentration in H63D cells was intermediate between wild-type and C282Y and
the ferritin concentration in S65C cells was similar to wild-type cells. Uptake of transferrin-iron in wild-type, C282Y and
control cells was measured over 45 min. The Hill coefficients for transferrin-iron uptake were similar. The Vmax for
transferrin-iron uptake in wild-type cells was 59.5% of control cells and 69.5% of C282Y cells. Estimates of Km were 232 nM
for wild-type cells, 338 nM for C282Y cells and 570 nM for controls. Transferrin receptor levels were lowered, but not
significantly, in the HFE transfected cells. The results show that HFE reduces transferrin-iron uptake, probably as an
uncompetitive inhibitor. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Hereditary haemochromatosis is an autosomal re-
cessive disorder of iron metabolism characterised by
increased iron absorption and the abnormal storage
of iron in parenchymal tissues [1]. In 1996, Feder et
al. [2] cloned the HFE gene and found that 85% of
haemochromatosis patients were homozygous for the
mutation C282Y, whilst many of the remainder were
compound heterozygotes for C282Y and a common
second mutation, H63D. More recently, another
HFE polymorphism, S65C, has been described [3].
The HFE mutations are common with allele frequen-
cies in South Wales of 8.2% for C282Y and 15.3%
for H63D [4] and 2.9% for S65C (G.P. Feeney and
M. Worwood, unpublished observation).
HFE is an MHC class I-like protein and has been
demonstrated to form a homodimeric complex with
L2-microglobulin [5,6], an association necessary for
the correct subcellular distribution of HFE. The
C282Y mutation, but not the H63D mutation, dis-
rupts both the subcellular distribution of HFE and
its association with L2-microglobulin [6]. The e¡ects
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of the S65C mutation have not been investigated.
The HFE protein is expressed strongly in placenta
[7], the duodenal crypts [8] and in liver Kup¡er cells
[9] and wild-type HFE co-immunoprecipitates with
the transferrin receptor, after chemical crosslinking,
from placenta and from human gut [7,10].
Investigations into the interaction between trans-
ferrin receptor and HFE have suggested that HFE
lowers the a⁄nity of transferrin receptor for diferric
transferrin [11,12], and that high concentrations of a
soluble form of HFE lower the a⁄nity in a dose-
dependent manner [11]. More recently, studies of
the interaction of soluble HFE with transferrin re-
ceptor and transferrin have revealed that HFE com-
petes with diferric transferrin for the two transferrin
binding sites on transferrin receptor [13]. HFE, trans-
ferrin receptor and transferrin can form a ternary
complex [14] in which transferrin receptor binds
one transferrin and one HFE. X-Ray crystallography
studies have revealed the structure of HFE and
shown that its peptide binding groove motif is the
area of interaction with transferrin receptor [15,16].
Studies of the e¡ects of HFE upon iron uptake by
cells have involved the arti¢cial expression of HFE
cDNAs within cultured cells. Roy et al. [17] demon-
strated that HFE expression reduced iron-55 uptake
from low concentrations of transferrin by about
33%, but did not a¡ect iron uptake from iron-
NTA. Further investigation revealed that the
changes were not due to alterations in the transferrin
receptor recycling rates, suggesting that HFE dimin-
ishes the acquisition of iron from endocytosed trans-
ferrin. Riedel et al. [18] demonstrated that high level
HFE expression reduced iron uptake from transfer-
rin at low transferrin concentrations and that HFE
increases the apparent Km (reduces a⁄nity) for trans-
ferrin receptor mediated iron uptake.
In order to investigate the e¡ects of wild-type and
mutant HFE proteins on cellular iron uptake, HFE
cDNAs were arti¢cially expressed in 293 cells and
their e¡ects upon transferrin receptor number, ferri-
tin concentration after culture with extra iron and
transferrin-iron uptake determined. Here, for the ¢rst
time, HFE is shown to reduce the uptake of trans-
ferrin-iron at a physiological transferrin concentra-
tion and the in vitro e¡ects of the common HFE
mutations upon HFE function are reported.
2. Materials and methods
2.1. Expression vectors and establishment of stable
transfectants
Wild-type, C282Y and H63D cDNAs were pro-
duced by RT-PCR of human cultured macrophage
RNA using HFE cloning primers identical, except
for the epitope tag sequence, to Feder et al. [5] : 5P-
gat cgg atc cac cat ggg ccc gcg agc cag gcc ggc gct tct
c-3P, incorporating a BamHII restriction site and 5P-
atg ccg tag cgg ccg ctt atc act tgt cat cgt cgt cgt ata
ggt cct cac gtt cag cta aga cgt ag-3P, incorporating a
C-terminal Xpress (Invitrogen) epitope tag, stop co-
dons and a NotI restriction site. S65C cDNA was
produced by PCR-based mutagenesis of the wild-
type cDNA. The cDNAs were ligated into
pcDNA3.1 vector (Invitrogen), cloned using Escheri-
chia coli and sequences were con¢rmed by cycle se-
quencing of the full-length inserts using primer sites
within the vector.
HEK 293 cells (a gift from Dr Gavin Wilkinson,
UWCM, Cardi¡, Wales, UK) were cultured in 10%
foetal bovine serum in HEPES bu¡ered DMEM with
penicillin and streptomycin. The cells were trans-
fected with the HFE expression vectors using a cal-
cium-phosphate transfection kit (Sigma). Stable
transfectants were selected and established on the
basis of resistance to 200 Wg/ml G418 base only.
2.2. RT-PCR and RNA blots
RNA was extracted from the transfected cells [19]
using RNazol B (Biogenesis) and RT-PCR per-
formed using the RNA PCR core kit (Perkin-Elmer).
RNA was DNase I treated, then random hexamer
reverse transcribed or ‘sham’ reverse transcribed
(no reverse transcriptase and no random hexamers).
HFE PCR was performed upon cDNA and the sham
RT reactions. For HFE mRNA, ampli¢cation was
over 37 cycles using the primers 5P-cag gac ctt ggt
ctt tcc ttg ttt g-3P and tgc tct cca atc cag tgt gtc agg-
3P. Control primers (gifts from Mr Steven Austin,
UWCM, Cardi¡, UK) for Abl mRNA were used.
The HFE probe for RNA blotting was produced
from CCF-STTG-1 human astrocytoma line RNA
using the HFE RT-PCR primers. The probe se-
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quence was con¢rmed to be that of HFE cDNA by
cycle sequencing.
Radiolabelled probe was used in Northern and slot
blot hybridisations to demonstrate HFE expression
in the transfected cells. The blots were stripped and a
GAPDH control probe (Clontech) was hybridised
against them. Hybridisations were carried out as de-
scribed by Sambrook et al. [20].
2.3. Immunoprecipitation and Western blot
Immunoprecipitations were performed as de-
scribed by Feder et al. [5]. Brie£y, 5U107 cells were
harvested and lysed in 1 ml lysis bu¡er (50 mM Tris-
HCl, 150 mM NaCl pH 7.5 with 0.5% Nonidet P40,
1 mM PMSF, 1 mM 1,10-phenanthroline, 1 mM
benzamidine) on ice for 1 h and the nuclei pelleted
by bench top centrifugation at 3000 rpm for 4 min.
The supernatant was removed and added to 6 Wg
anti-L2-microglobulin antibody (Clone B1G6, Immu-
notech) and incubated on a roller at 4‡C for 1 h.
MHC class I molecules bound to the B1G6 antibody
were precipitated by incubation with protein-G
Sepharose (Sigma, 0.65 mg human IgG binding ca-
pacity) for 1 h at 4‡C and the Sepharose bound pro-
tein complex washed at 4‡C six times in 1 ml lysis
bu¡er, pelleted, aspirated and denatured in 50 Wl
Laemmli bu¡er. The Sepharose was again pelleted,
the supernatant removed and stored at 370‡C until
required for SDS-PAGE. SDS-PAGE was performed
with the entire 50 Wl sample per lane and the gel
electroblotted onto Hybond C membrane and
probed using the Xpress (epitope tag) monoclonal
antibody (Invitrogen) or a polyclonal antibody raised
against the HFE K2 domain (a gift of Dr Bill Grif-
¢ths and Prof. Tim Cox, University of Cambridge,
UK). Detection was via peroxidase conjugated sec-
ondary antibodies (Sigma) followed by enhanced
chemiluminescence (Roche).
Immuno£uorescent stains of all of the transfected
cells were produced by culturing them on glass slides,
then drying, ¢xing and staining them with HFE-JB1
antibody as described by Bastin et al. [9]. HFE-JB1
staining was detected indirectly using a goat anti-
mouse FITC antibody (Sigma). The slides were cov-
ered and inspected using a Zeiss Axiophot £uores-
cent microscope.
2.4. Iron uptake experiments (ferritin)
Cells were seeded at 5U105 per 25 cm2 £ask in 4 ml
medium with 0 WM or 40 WM ferric iron as ferric
ammonium citrate and cultured for 5 days until
semi-con£uent. Cells were harvested by scraping
and pelleted, then resuspended into a hypotonic lysis
bu¡er (5 mM phosphate bu¡ered saline, 1 mM
EDTA) and freeze-thawed three times at 370‡C.
The nuclei were pelleted and the supernatant assayed
for ferritin (Elecsys 2010 Serum Ferritin Assay,
Boehringer Mannheim) and the total supernatant
protein estimated by the Lowry method. Ferritin/
protein ratios (0 and 40 WM iron) were obtained
for the transfected cells.
2.5. Transferrin-iron-55 uptake experiments
Human apo-transferrin (iron saturation 6 5%, to-
tal iron binding activity 80% of total protein concen-
tration) was obtained from Sigma and loaded to 64%
saturation using iron-55 ferric citrate, prepared from
iron-55 ferric chloride (NEN Life Science) using a
25-fold molar excess of sodium citrate. The transfer-
rin saturation was determined by absorbance at
465 nm. In order to detect non-transferrin bound
iron in the transferrin preparation, the iron-loaded
transferrin was analysed by gel ¢ltration using a G-
25 Sephadex column. No non-transferrin bound iron
was detected.
For the iron uptake experiments, 2U105 cells for
each transfectant were seeded per 10 cm2 well and
grown overnight in complete medium. Thirty min-
utes before the experiment, cells grown as controls
for non-speci¢c transferrin binding were placed on
ice and the medium of all cells changed to serum-
free. At time zero, transferrin-iron was added to the
test cells at 37‡C and to the controls on ice and all
the cells incubated for 45 min. Uptake/binding was
stopped by aspiration of medium followed by trypsi-
nisation and transfer of the cells to 1.5 ml micro-
tubes. The cells were pelleted and washed three times
in 1 ml 1% foetal bovine serum in 50 mM PBS pH
7.5. The cell supernatants were aspirated, 50 Wl ferric
ammonium citrate (5 mg/ml) added as carrier iron
and 500 Wl 0.1 M HCl added. The iron-55 was
dissolved by incubation at 55‡C for 90 min. Radio-
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activity of the acid supernatants was determined by
liquid scintillation counting. Radioactivity for cells
left on ice was subtracted from radioactivity for cells
incubated at 37‡C to obtain corrected iron uptake
data. Cell counts were obtained from cells cultured
in wells to which no radiation was added. Because
the transferrin receptor has two transferrin binding
sites, the kinetic data were used to construct a Hill
plot to estimate the Hill coe⁄cients by linear regres-
sion analysis. The estimates of the Hill coe⁄cients
and the raw kinetic data were then used to calculate
the apparent Vmax and Km values by mathematical
curve ¢t [21] to the Hill equation.
2.6. Determination of transferrin receptor numbers
The transfected cells were seeded at 105 per 10 cm2
well and grown overnight. The cells were harvested
by gently rinsing in medium and were ¢xed and per-
meabilised using the Leucoperm kit (Serotec). Cells
were stained using mouse anti-human CD71 RPE
(Serotec) or its isotype-speci¢c mouse control IgG1
negative control RPE (Serotec) and mean £uorescent
intensity determined by £ow cytometry. Transferrin
receptor numbers were mean £uorescent intensity
from CD71 antibody minus control intensity. Experi-
ments were performed simultaneously for the ¢ve cell
lines.
3. Results
3.1. HFE mRNA expression
Northern blot hybridisations of the RNA from the
transfected cells detected transfected HFE mRNA
bands of approx. 1.3 kb in all of the HFE transfected
cells lanes (Fig. 1). No HFE mRNA expression was
detected in the empty vector transfected control cells.
When the membrane was stripped and re-probed us-
ing the GAPDH control probe, bands of approx.
1.6 kb were detected in all of the lanes. These obser-
vations were con¢rmed by Slot blot and RT-PCR
analysis (not shown).
3.2. Immunoprecipitation, Western blotting and
immuno£uorescent staining
Immunoprecipitation followed by Western blot
analysis using the Xpress antibody (Fig. 2A) or the
anti-peptide ‘Dallas’ antibody (Fig. 2B) yielded HFE
protein of size 43 kDa/45 kDa in the cells transfected
with wild-type HFE cDNA, but not in control cells
transfected with empty vector. Some very faint bands
consistent with HFE antibody cross-reaction with
the high levels of MHC class I protein present were
detected in the control lane. The HFE protein was
expressed at a low level and immunoprecipitation
was necessary for its detection. The immuno£uores-
Fig. 1. Northern blot analysis of the transfected cells. Northern
blots for the transfected cells were hybridised with a radiola-
belled cDNA probe speci¢c for HFE mRNA and exposed to
X-ray ¢lm. The membranes were then stripped and hybridised
with a GAPDH cDNA probe. Wild-type (W), C282Y (C),
H63D (H) and S65C (S) cells expressed HFE mRNA at similar
levels. Even with excess RNA loaded, no HFE mRNA could
be detected in the control. The control bands are from the
same experiment as those of the HFE transfectants, other sam-
ples have been excised from the images.
Table 1
Comparison of ferritin concentrations in the HFE transfected cells using the paired t-test
Cell type P-value vs. controls P-value vs. C282Y P-value vs. wild-type
Wild-type 0.013 0.0001
C282Y 0.109 0.0001
H63D 0.004 0.122 0.323
Controls 0.109 0.013
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cent staining of the transfected cells showed that all
of the cells in each of the HFE transfected lines ex-
pressed HFE protein (not shown), whilst the control
cells did not. The staining was weak, suggesting that
the level of HFE protein expression was low.
3.3. Ferritin accumulation
The e¡ects of HFE expression upon ferritin accu-
mulation in response to an iron challenge (ferric am-
monium citrate) are shown in Fig. 3. The highest
ferritin concentration was in the control cells which
did not express HFE, whilst the cells expressing wild-
type and S65C HFE had the lowest ferritin concen-
trations. Cells expressing wild-type, H63D and S65C
HFE accumulated signi¢cantly less ferritin (paired
t-test P6 0.05) than the control cells (Table 1). The
ferritin concentration in H63D cells was intermediate
between wild-type and C282Y cells. The ferritin con-
centration in C282Y cells was not signi¢cantly lower
than in the controls (paired t-test P = 0.109).
3.4. Transferrin iron-55 uptake
In order to con¢rm that ferritin response was a
good index of iron uptake and to further study the
e¡ects of HFE upon iron uptake, the uptake of iron-
55 from 64% saturated human transferrin was mea-
sured in wild-type, C282Y and control cells (see Fig.
4). Hill plots of the kinetic data followed by linear
regression analysis showed that estimates of the Hill
coe⁄cients for transferrin-iron uptake were similar
(see Table 2); the values were less than 1, suggesting
that there was some allosteric, negative cooperativity
between the transferrin binding sites in this system.
The Hill coe⁄cients were used to analyse the kinetic
data by curve ¢t to the Hill equation (Fig. 4). The
Vmax of transferrin-iron uptake in wild-type cells was
59.5% of the Vmax for the control cells and 69.5% of
Fig. 2. Immunoprecipitation of HFE protein from wild-type
cells, but not control cells. MHC class I molecules were immu-
noprecipitated from lysates of wild-type and control cells using
anti-L2-microglobulin antibody and separated by reducing SDS-
PAGE, then Western blotted. HFE protein was detected using
(A) anti-Xpress antibody revealing a double band of HFE pro-
tein at about 45 kDa and (B) a similar result using the Dallas
polyclonal antibody. The large bands at 31^36 kDa represent
polypeptides from the L2-microglobulin antibody, as detected
by the secondary anti-mouse antibody.
Fig. 3. Ferritin concentrations in HFE transfectants are lower
than in controls after 5 days culture in 40 WM added iron. The
ferritin concentrations as a result of 5 days culture in 40 WM
iron (Final) and 5 days culture in 0 WM iron (Initial) are shown
as a percentage of the control ¢nal concentration. Wild-type
cells accumulated the least ferritin (69% of control or 81% of
C282Y). Wild-type, H63D, and S65C cells accumulated statisti-
cally signi¢cantly less ferritin than the control cells (see Table
1). The histogram represents paired data from seven experi-
ments.
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the Vmax for the C282Y cells (Table 2). The apparent
Km of transferrin-iron uptake in wild-type cells was
40.7% of that of control cells and 68.6% of that of
C282Y cells, suggesting that the cellular transferrin
receptor a⁄nity for partially saturated transferrin
was greater in wild-type cells than C282Y or control
cells (Table 2). These changes to the Km and Vmax
values in wild-type cells are consistent with the ac-
tions of HFE as an uncompetitive inhibitor [21]. At
the physiological concentration of 2 mg/ml transfer-
rin (64% saturated), the di¡erences between wild-
type, C282Y and control cells persisted (Fig. 4).
3.5. Transferrin receptor numbers
Transferrin receptor numbers were determined, in
¢xed and permeabilised cells, by £ow cytometry. The
mean £uorescent intensity of the cells following
staining with PE labelled anti-transferrin receptor
antibody was determined (summarised in Fig. 5A).
The expression of HFE appeared to reduce transfer-
rin receptor numbers in 293 cells, though the trans-
Fig. 4. (A) Transferrin iron uptake as a function of transferrin
concentration in wild-type, C282Y and control cells. Iron-55
uptake from 64% saturated transferrin after 45 min incubation
at 37‡C (corrected for non-speci¢c binding) is shown for wild-
type, C282Y and control cells. Wild-type cells took up consis-
tently less iron-55 than C282Y or control cells over a range of
subphysiological transferrin concentrations and at the physio-
logical concentration of 2000 mg/l. The di¡erences remained at
saturating transferrin concentrations and the graph indicates
that wild-type HFE reduced the Vmax of transferrin-iron uptake.
Data points are means þ S.E.M. for three experiments (except
C282Y curve 2000 mg/l transferrin point where n = 1). (B) The
raw curve ¢ts against the Hill equation for the wild-type,
C282Y and control cells ; iron uptake is expressed in arbitrary
units. The diamonds indicate the actual iron uptake data, whilst
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ferrin receptor numbers were variable and the di¡er-
ences failed to reach statistical signi¢cance (paired t-
test). Fig. 5B shows typical histograms for transferrin
receptor staining in the wild-type, C282Y and empty
vector transfected cells. The distribution of the trans-
ferrin receptor staining, as compared to the empty
vector cells, demonstrates that each cell type con-
tained a single population of cells staining for trans-
ferrin receptors. Although small, the di¡erences be-
tween the controls and C282Y (P = 0.051) and
between controls and wild-type cells (P = 0.054)
neared statistical signi¢cance.
4. Discussion
HFE mRNA expression was detected at similar
levels in the HFE transfected cells but not in the
control cells. HFE protein expression was demon-
strated by Western blotting (Fig. 2). The faint bands
in the control lane are suggestive of minor antibody
cross-reactivity with the highly enriched MHC class I
proteins puri¢ed during the immunoprecipitation
procedure. Immuno£uorescent staining demon-
strated uniform HFE protein expression in each
HFE transfected cell line. A model for wild-type
and mutant HFE expression has been produced in
which HFE expression may be studied upon a back-
ground of no HFE expression in the control cells.
HFE expression reduced ferritin accumulation by
31% in wild-type cells compared to control cells, a
result similar to that obtained by Roy et al. [17], who
measured a decrease of 33% in transferrin-iron up-
take in HeLa cells arti¢cially expressing wild-type
HFE cDNA. In contrast, Riedel et al. [18] found
that high levels of HFE expression halved cellular
ferritin accumulation in HeLa cells, whilst there
have been reports that high levels of HFE expression
can cause a 10-fold reduction in cellular ferritin ac-
cumulation [12,22]. The e¡ects of in vitro HFE ex-
pression may depend upon the level of expression
and this study demonstrates that even when the level
of HFE expression is low, HFE can still diminish
iron uptake and ferritin accumulation.
The HFE polymorphisms had varying e¡ects upon
this HFE function. The C282Y mutation, the most
common in haemochromatosis patients, has previ-
ously been reported to prevent presentation of the
Fig. 5. The e¡ects of HFE expression upon transferrin receptor
numbers in 293 cells. (A) Transferrin receptor numbers for the
HFE transfectants are expressed as percentage of the control
cell number. None of the HFE transfectants had transferrin re-
ceptor numbers that were statistically signi¢cantly di¡erent
from the controls. The ¢gure shows means of data from six
paired experiments. (B) The overlaid histograms show the typi-
cal distribution of transferrin receptor staining for each of the
transfected cells. The peak drawn with a thin line, separate
from the rest, represents wild-type cells stained with the control
antibody, the thick line represents wild-type cells stained for
transferrin receptor, the pecked line represents C282Y cells and
the dashed line control cells.
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protein at the cell surface [6] and possibly the asso-
ciation of HFE with the transferrin receptor [7,11].
This study shows that the C282Y mutation a¡ects
HFE function, so that total ferritin accumulation
by C282Y cells was 121% of that of wild-type cells
(P = 0.013, n = 7). Less clear was the di¡erence be-
tween HFE C282Y expressing cells and the control
cells. Although not statistically signi¢cant, the mean
C282Y cell ferritin level remained lower than in con-
trol cells adding to the evidence from HFE knockout
mice that HFE C282Y is not a null mutation [23].
The H63D mutation had less e¡ect than C282Y,
probably re£ecting the fact that the H63D mutation
does not seem to alter HFE subcellular distribution
[6]. These results con¢rm the perception of H63D is a
‘milder’ mutation than C282Y. The more recently
reported HFE mutation, S65C, seemed to have little
e¡ect upon ferritin accumulation. One possible
mechanism by which the HFE C282Y and H63D
mutations may decrease HFE activity is by decreas-
ing the stability of the protein. The immuno£uores-
cent staining detected no gross di¡erences in the lev-
els of HFE protein expression in the di¡erent cell
lines; however, there is evidence that the C282Y mu-
tation leads to the accelerated degradation of the
protein [6].
In order to investigate the e¡ects of HFE further,
transferrin-iron uptake was measured in the wild-
type, C282Y and control cells. Previously there
have been reports that HFE reduces the a⁄nity of
transferrin receptors for labelled transferrin in cells
[11,13,24]. Feder et al. [11] concluded, following
Scatchard analysis, that HFE reduces the cellular
a⁄nity for transferrin. However, close inspection of
the raw plots of transferrin binding as a function of
transferrin concentration reveals that it is the number
of transferrin binding sites that is lower in wild-type
cells and not the cellular a⁄nity for transferrin. In
agreement with this revised interpretation, Salter-Cid
et al. [25] produced very similar transferrin binding
curves for HFE transfected HeLa cells, determined
that HFE did not a¡ect the cellular a⁄nity for trans-
ferrin binding and demonstrated that HFE reduces
the number of transferrin binding sites. In support of
these observations, Ikuta et al. [26] measured the
e¡ects of HFE expression upon the binding of 125I
labelled transferrin to the human hepatoma cell line
HLF. HFE expression reduced maximal transferrin
binding by about 20% and the Kd for cellular trans-
ferrin binding was increased from 1.9 nM to 4.3 nM,
indicating that cellular a⁄nity for transferrin was
only slightly decreased by HFE overexpression [26].
In contrast, the cellular Kd for transferrin binding, as
determined by Scatchard analysis, was increased 9-
fold by HFE expression in HeLa cells [12], whilst
Lebron et al. [13] used transferrin binding assays
performed upon plate bound transferrin receptor
protein in the absence and presence of HFE protein
to show that, in a cell free system, micromolar con-
centrations of HFE resulted in a diminished trans-
ferrin receptor a⁄nity for diferric transferrin. Riedel
et al. [18] found that the cellular a⁄nity for trans-
ferrin-iron uptake was decreased by HFE expression
so that at saturating, but subphysiological, levels of
transferrin HFE did not a¡ect transferrin-iron up-
take. However, observations that HFE reduces trans-
ferrin receptor a⁄nity for transferrin are di⁄cult to
relate to the saturating transferrin concentrations
seen in vivo.
In this study, transferrin saturated to 64% with
iron-55 was used and iron uptake studied over a
range of transferrin concentrations. Hill coe⁄cients
for transferrin-iron uptake were estimated because
the transferrin receptor has two binding sites for
transferrin. Two research groups have reported Hill
coe⁄cients for the transferrin receptor of about 1.0
Table 2
Estimates of the Hill coe⁄cients, Vmax and Km values for transferrin-iron uptake in wild-type, C282Y and control cells
Cell type Vmax (pmol iron per million cells) 45 min Km (nM (mg/l)) Hill coe⁄cient
Wild-type 24.4 232 (18.8) 0.73
C282Y 35.1 338 (27.4) 0.65
Control 41.0 570 (46.1) 0.63
The values are for transferrin-iron uptake over 45 min at 37‡C (corrected for ‘uptake’ on ice). The Hill coe⁄cients were similar and
less than 1. The Vmax of iron uptake in wild-type cells was 59.5% of that for control cells and 69.5% of that for C282Y cells. HFE ex-
pression substantially reduced the Km for transferrin-iron uptake.
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[27] using steady state radiolabelled transferrin bind-
ing assays. In this kinetic study, the Hill coe⁄cients
in wild-type, C282Y and control cells were similar
and less than 1.0, indicating that the transferrin re-
ceptor homodimer was subject to allosteric changes
which caused some negative cooperativity between
the transferrin binding sites. The apparent Km values
for transferrin-iron uptake were reduced in the
C282Y and wild-type cells when compared to the
controls, suggesting that HFE may slightly increase
the a⁄nity for transferrin-iron uptake. The Km esti-
mates were higher than in other studies [11,15,25]
because the data were generated using a lower trans-
ferrin saturation and higher transferrin concentra-
tions. The apparent Vmax of iron uptake was mark-
edly decreased in the wild-type cells, indicating, with
the decrease in Km, that wild-type HFE may act as
an uncompetitive inhibitor [21] of transferrin-iron
uptake. The e¡ects of HFE and the di¡erence in
function between C282Y and wild-type HFE per-
sisted at the physiological transferrin concentration
of 2 mg/ml (25 WM), indicating the relevance of these
in vitro observations to HFE function in vivo. This is
the ¢rst report that HFE expression reduces trans-
ferrin-iron uptake at saturating and physiological
concentrations and provides the ¢rst in vitro evi-
dence that HFE expression may reduce cellular
transferrin-iron uptake in vivo.
In enzyme kinetic terms Vmax may be reduced by a
reduction in the amount of available enzyme, in this
case the number of transferrin receptors. The trans-
ferrin receptor levels in cells with small iron stores, in
early log phase growth, were measured. In agreement
with the results of Ikuta et al. [26], HFE expression
reduced the number of transferrin receptors by
around 20%, but these di¡erences did not achieve
statistical signi¢cance. The transferrin receptor num-
bers in C282Y cells were lower than in wild-type
cells, but iron uptake was much greater in the
C282Y cells than in the wild-type cells, so that cel-
lular transferrin receptor number did not correlate
with iron uptake. This indicates that the e¡ect of
HFE expression on the number of cellular transferrin
receptors is a minor factor.
If transferrin receptor number per se is not impor-
tant, then HFE may act upon the transferrin recep-
tor population to reduce iron uptake by rendering
transferrin receptors unavailable for iron uptake or
by slowing receptor cycling and the release of iron
from endocytosed holo-transferrin. It has been re-
ported that HFE expression does not a¡ect the rate
of transferrin receptor cycling [17] but there are re-
ports that it does [25,26]. The inhibition of transfer-
rin-iron uptake by HFE has kinetics characteristic of
an uncompetitive inhibitor, suggesting that HFE
binds only transferrin receptor already bound to
holo-transferrin to form the ternary complexes de-
scribed by Lebron and Bjorkman [14]. If this is so,
HFE may act to inhibit transferrin-iron uptake by
slowing of the release of transferrin bound iron
into the cell after endocytosis.
This study con¢rms that expression of the HFE
protein reduces cellular iron uptake and ferritin ac-
cumulation. The common HFE mutations C282Y
and H63D disrupted the function of HFE, whilst
the S65C mutation did not. This report presents evi-
dence that the HFE protein acts not by altering the
a⁄nity of the transferrin receptor for transferrin, but
the Vmax of transferrin-iron uptake, so that the HFE
protein continues to limit transferrin-iron uptake
even at physiological transferrin concentrations.
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